FOLH1 and prostate carcinoma: Although 111 Indium labeled Cyt-356/ProstaScint was approved for detecting occult prostate cancer recurrence in 1996, applying PSMA PET to stage high-risk prostate cancer was not widely adopted until after the approval of the more sensitive and more specific [68Ga] Ga-PSMA-11 in December 2020.